PMID- 33402184
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 1471-2474 (Electronic)
IS  - 1471-2474 (Linking)
VI  - 22
IP  - 1
DP  - 2021 Jan 5
TI  - Upfront surgery is not advantageous compared to more conservative treatments such 
      as observation or medical treatment for patients with desmoid tumors.
PG  - 12
LID - 10.1186/s12891-020-03897-9 [doi]
LID - 12
AB  - BACKGROUND: This study compared the clinical and functional outcomes of patients 
      initially treated with observation or medical treatment with those of patients 
      treated with local treatment (surgery alone or surgery with adjuvant 
      radiotherapy) to confirm whether observation or medical treatment is an 
      appropriate first-line management approach for patients with desmoid tumors. 
      METHODS: We retrospectively reviewed the medical records of 99 patients with 
      histologically confirmed primary desmoid tumors treated between 1978 and 2018. 
      The median follow-up period was 57 months. We evaluated event-free survival, 
      defined as the time interval from the date of initial diagnosis to the date of 
      specific change in treatment strategy or recurrence or the last follow-up. 
      RESULTS: An event (specific change in treatment strategy or recurrence) occurred 
      in 28 patients (28.3%). No significant difference in event-free survival was 
      found between the first-line observation/medical treatment and local treatment 
      groups (p = 0.509). The median Musculoskeletal Tumor Society score of the 
      patients treated with first-line local treatment was 29 (interquartile range 
      [IQR], 23-30), whereas that of the patients managed with first-line observation 
      or medical treatment was 21 (IQR, 19-29.5). First-line observation or medical 
      treatment was more frequently chosen for larger tumors (p = 0.045). In the 
      patients treated with local treatment, local recurrence was not related to the 
      surgical margin (p = 0.976). CONCLUSION: Upfront surgery is not advantageous 
      compared to more conservative treatments such as observation or medical treatment 
      for patients with desmoid tumors.
FAU - Tsukamoto, Shinji
AU  - Tsukamoto S
AUID- ORCID: 0000-0002-8419-2008
AD  - Department of Orthopaedic Surgery, Nara Medical University, 840, Shijo-cho, 
      Kashihara-city, Nara, 634-8521, Japan. shinji104@mail.goo.ne.jp.
FAU - Tanzi, Piergiuseppe
AU  - Tanzi P
AD  - Department of Orthopaedic Oncology, IRCCS Istituto Ortopedico Rizzoli, Via 
      Pupilli 1, 40136, Bologna, Italy.
FAU - Mavrogenis, Andreas F
AU  - Mavrogenis AF
AD  - First Department of Orthopaedics, National and Kapodistrian University of Athens, 
      School of Medicine, 41 Ventouri Street, Holargos, 15562, Athens, Greece.
FAU - Akahane, Manabu
AU  - Akahane M
AD  - Department of Health and Welfare Services, National Institute of Public Health, 
      2-3-6 Minami, Wako-shi, Saitama, 351-0197, Japan.
FAU - Kido, Akira
AU  - Kido A
AD  - Department of Rehabilitation Medicine, Nara Medical University, 840 Shijo-cho, 
      Kashihara-city, Nara, 634-8521, Japan.
FAU - Tanaka, Yasuhito
AU  - Tanaka Y
AD  - Department of Orthopaedic Surgery, Nara Medical University, 840, Shijo-cho, 
      Kashihara-city, Nara, 634-8521, Japan.
FAU - Cesari, Marilena
AU  - Cesari M
AD  - Department of Medical Oncology, IRCCS Istituto Ortopedico Rizzoli, Via Pupilli 1, 
      40136, Bologna, Italy.
FAU - Donati, Davide Maria
AU  - Donati DM
AD  - Department of Orthopaedic Oncology, IRCCS Istituto Ortopedico Rizzoli, Via 
      Pupilli 1, 40136, Bologna, Italy.
FAU - Longhi, Alessandra
AU  - Longhi A
AD  - Department of Medical Oncology, IRCCS Istituto Ortopedico Rizzoli, Via Pupilli 1, 
      40136, Bologna, Italy.
FAU - Errani, Costantino
AU  - Errani C
AD  - Department of Orthopaedic Oncology, IRCCS Istituto Ortopedico Rizzoli, Via 
      Pupilli 1, 40136, Bologna, Italy.
LA  - eng
PT  - Journal Article
DEP - 20210105
PL  - England
TA  - BMC Musculoskelet Disord
JT  - BMC musculoskeletal disorders
JID - 100968565
SB  - IM
MH  - Conservative Treatment
MH  - *Fibromatosis, Aggressive/surgery
MH  - Humans
MH  - Neoplasm Recurrence, Local/epidemiology/therapy
MH  - Radiotherapy, Adjuvant
MH  - Retrospective Studies
PMC - PMC7784367
OTO - NOTNLM
OT  - Active surveillance
OT  - Aggressive fibromatosis
OT  - Desmoid tumor
OT  - MSTS functional score
OT  - Surgery
COIS- The authors declare that they have no competing interests.
EDAT- 2021/01/07 06:00
MHDA- 2021/05/15 06:00
PMCR- 2021/01/05
CRDT- 2021/01/06 05:29
PHST- 2020/06/21 00:00 [received]
PHST- 2020/12/21 00:00 [accepted]
PHST- 2021/01/06 05:29 [entrez]
PHST- 2021/01/07 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
PHST- 2021/01/05 00:00 [pmc-release]
AID - 10.1186/s12891-020-03897-9 [pii]
AID - 3897 [pii]
AID - 10.1186/s12891-020-03897-9 [doi]
PST - epublish
SO  - BMC Musculoskelet Disord. 2021 Jan 5;22(1):12. doi: 10.1186/s12891-020-03897-9.